LGND Q4 2022 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M-62.7% YoY

Gross Profit

$5M20.1% margin

Operating Income

$12M45.0% margin

Net Income

-$17M-64.7% margin

EPS (Diluted)

$-1.04

QoQ Revenue Growth

-54.3%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$51M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$763M

Total Liabilities

$165M

Stockholders' Equity

$597M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$72M	-62.7%
Gross Profit	$5M	$60M	-91.0%
Operating Income	$12M	$13M	-4.4%
Net Income	-$17M	-$5M	-222.8%

Revenue Segments

Material Sales, Captisol

$27M34%

Material Sales, Captisol, COVID

$24M30%

Royalty

$21M27%

Royalty, Other

$4M5%

Material Sales, Captisol, Core

$3M4%